wow this thing moves on air

buying

$LMNX FDA Corona Approved Test Next?

$DHR just got FDA fast track approval over the weekend for their Cepheid Gene Xpert Flu test.

https://www.mercurynews.com/2020/03/21/coronavirus-test-45-minute-cepheid-sunnyvale-covid-19-test/

$LMNX has a VERY similar product called the Luminex Aires system that was approved by the FDA in 2016.

https://www.genomeweb.com/regulatory-news/luminex-receives-fda-clearance-influenza-ab-respiratory-syncytial-virus-assays#.XnebZNJKhPY

In fact the $DHR Cepheid Gene Xpert & Luminex Aires are considered the leading test systems for flu genes.

https://www.luminexcorp.com/download/comparison-cepheid-gene-xpert-flursv-xc-gx-luminex-aries-flu-ab-rsv-la-simplexa-flu-ab-rsv-direct-s-assays/

I would keep this one on watch, because $LMNX already stated last week that they are trying to get FDA EUA testing approval for the corona virus as well. Even though $DHR was the first, it is going to take way more than one test provider to meet world wide demand for these tests.

-Four independent clinical laboratories report data from evaluation of automated, sample-to-answer ARIES® System for rapid detection of SARS-CoV-2 virus

-Luminex has launched and begun shipping its Research Use Only (RUO) NxTAG® CoV Extended Panel

-Luminex is planning to submit an EUA (Emergency Use Authorization) for its NxTAG® CoV Extended Panel (RUO) by the end of this month

-Luminex intends to submit an EUA for an ARIES® SARS-CoV-2 Assay next month

https://finance.yahoo.com/news/luminex-provides-sars-cov-2-113000459.html

Looks like the FDA fast tracked a $lmnx caronavirus test. .

the markets say that grease is the word for the downward slip, opps I mean greece.

this thing is going in the wrong direction :(

insider buying
should hear something in the next couple of months

we will climb when they announce the launch or Aries to the FDA this summer. go LMNX (long)

~ $LMNX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $LMNX ~ Earnings expected on Monday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=LMNX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=LMNX&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/LMNX?
~ OTC Markets: http://www.otcmarkets.com/stock/LMNX/company-info
~ Google Finance: http://www.google.com/finance?q=LMNX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=LMNX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=LMNX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=LMNX
Finviz: http://finviz.com/quote.ashx?t=LMNX
~ BusyStock: http://busystock.com/i.php?s=LMNX&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=LMNX&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=LMNX
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=LMNX
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=LMNX
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=LMNX
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=LMNX
~ MarketWatch: http://www.marketwatch.com/investing/stock/LMNX/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=LMNX
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LMNX
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LMNX&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LMNX&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LMNX&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Luminex Shares Fly On Flu Test
Andy Stone, 01.03.08, 4:35 PM ET


This year’s flu season is already under way, but Luminex (nasdaq: LMNX - news - people ) has just the thing to help doctors and their patients beat back the infection next year. On Wednesday the U.S. Food and Drug Administration approved the Luminex xTAG Respiratory Viral Panel, a DNA-based test that can determine within hours the specific cause of respiratory infection such as the flu, helping doctors to quickly get patients on the right treatment. The technology could replace older tests that rely on cell culture, and often take three or more days to provide results.

Shares of the Austin, Tex. company rose 79 cents, or 4.9%, to $17.02, on Thursday.

The Viral Panel allows doctors to simultaneously search for 12 viruses that cause 85% of all respiratory infections, reducing the pressure to prescribe antibiotics as a precautionary measure until bacterial infection can be ruled out. Overuse of antibiotics is thought to be a major cause of bacterial resistance.

Patrick J. Balthrop, the Luminex chief executive, said 1 million tests are run for respiratory infections each year using existing technologies, a $75 million market. Luminex’s total sales for 2006 were $53 million.

The Viral Panel is based on the xMAP molecular diagnostic platform that Luminex has been selling to drug research labs since 1999. The xMAP bioassay allows researchers to look directly at the molecules that cause disease – DNA and proteins – and observe how drugs interact with these molecules.

The market for clinical molecular diagnostics was expected to grow by 20% in 2007, to $1.7 billion, as doctors adopt the tests to rapidly diagnose disease and search for genetic disorders.

“There is a well-trod path from research to clinical lab for processing technologies,” says John L. Sullivan, analyst with Leerink Swann. “Luminex has proven its results to be reproduceable in research labs at drug companies, then moved to the clinic.”

Luminex already markets a molecular test to determine the risk that children will be born with cystic fibrosis when both parents are carriers for the disorder.

But the flu is much more common. “It shows clinicians how useful the Luminex platform is, and then Luminex can go forward and develop other tests as well,” says Sullivan.

The key feature of Luminex’s xMAP platform is its ability to check for up to up to 100 different types of molecules simultaneously, in samples that may be relatively impure. The Viral Panel uses microscopic beads that change color in the presence of DNA from any of 12 different viruses. A $70,000 Luminex analyzer detects the color change. Luminex has sold 40,000 such analyzers for use in research labs.

Existing cell culture-based diagnostics require individual tests for each molecule, while high-throughput screens from companies such as Agilent Technologies (nyse: A - news - people ) and Affymetrix (nasdaq: AFFX - news - people ) excel at scanning for thousands of different types of molecules that are needed in drug discovery efforts.

Luminex’s core business has been the manufacture and sale of bioassay consumables and devices to clinical research companies including Celera Group, Abbott Labs (nyse: ABT - news - people ) and Bayer (nyse: BAY - news - people ). These companies package Luminex’s consumables into test kits that are sold to labs.

Last March, however, the company bought Tm Bioscience of Toronto, which developed the cystic fibrosis test based on Luminex’s xMAP platform and gives Luminex a direct sales channel to clinics. Luminex now sells that test, and will sell the Viral Panel via its Luminex Molecular Diagnostics subsidiary.

Shares of Luminex Rise on FDA Approval
Thursday January 3, 7:53 pm ET
Luminex Shares Hit Year High As FDA Clears Test for Detecting 12 Strains of Respiratory Virus

WASHINGTON (AP) -- Shares of Luminex Corp., a biological testing company, jumped to a new annual high Thursday after federal regulators approved the company's test to detect 12 different strains of respiratory virus.

The company's stock rose 79 cents, or 4.9 percent, Thursday to $17.02. Earlier in the day, the stock hit a 52-week high of $17.87.

The Toronto-based diagnostic maker's xTAG Respiratory Viral Panel is the first test to use genetic material to detect multiple viruses at the same time.

Physicians use the test on a small genetic sample taken from the back of a patients' throat. During the testing process, microscopic beads bind to any material infected with the virus. These beads are then sorted so specific infections can be identified.

FDA said the test is the first to distinguish between influenza A subtypes H1 and H3. Influenza A is the most serious form of the virus and has caused major epidemics around the world.